Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
09/2005
09/27/2005US6949535 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one
09/27/2005US6949510 Uses of diterpenoid triepoxides as an anti-proliferative agent
09/27/2005US6949349 incubating a phagemid clone displaying the peptide, with the IGF in the presence of the IGFBP at high and low concentrations of the phagemid clone, measuring the degree to which binding of the phagemid clone to the IGFBP is inhibited by IGF
09/27/2005US6949263 Method for preparing nicotianamine or nicotianamine-containing product
09/27/2005CA2120942C Nitric esters of derivatives of the 2-(2,6-di-halo-phenylamino)phenyl-acetic acid and process for their preparation
09/22/2005WO2005087925A1 Recombinant gene, disease animal model and method of evaluating test substance
09/22/2005WO2005087775A1 Tricyclic heterocyclic compound and medicinal composition containing the compound as active ingredient
09/22/2005WO2005087749A1 2-aminoquinazoline derivative
09/22/2005WO2005087713A1 Amide compound, pharmaceutical composition and rxr function control agent
09/22/2005WO2005087701A1 Novel 2-(α -n-pentanonyl)benzoates, their preparation and use
09/22/2005WO2005087249A1 Protease inhibitor and preventives or remedies for diseases
09/22/2005WO2005087247A1 Blood cholesterol level-lowering agent
09/22/2005WO2005087242A1 Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method
09/22/2005WO2005087237A1 Fasudil-containing preparation and method of improving stability thereof
09/22/2005WO2005087182A1 Functional powders
09/22/2005WO2003065997A3 Anti-infarction molecules
09/22/2005WO2000075279A3 Nucleotide sequences for gene regulation and methods of use thereof
09/22/2005US20050209452 Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
09/22/2005US20050209338 Phenethanolamine derivatives for treatment of respiratory diseases
09/22/2005US20050209329 Potentiation of therapeutic effects of fatty acids
09/22/2005US20050209325 Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
09/22/2005US20050209310 Methods for modulating tumor growth and metastasis
09/22/2005US20050209286 RXR activating molecules
09/22/2005US20050209281 Salt formation by dissolving donepezil in ethanol, adding hydrogen chloride, forming polymorphic crystal; simplification; safety to environment and the bodies of operators; and can produce at low costs
09/22/2005US20050209273 Neuroprotectants, analgesics or anticonvulsants
09/22/2005US20050209270 Use of 5HT3 agonists for relaxing the fundus
09/22/2005US20050209261 Rho-kinase inhibitors
09/22/2005US20050209253 Corticotropin releasing factor (CRF) receptor antagonists; nervous system disorders, ischemia, gastrointestinal disorders, hypertension, eating disorders, sleep disorders; e.g. 2-(1-[7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperidin-2-yl)-ethanol
09/22/2005US20050209252 Using an indazole compound
09/22/2005US20050209244 N{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
09/22/2005US20050209240 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors
09/22/2005US20050209234 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds
09/22/2005US20050209233 Neuropeptide Y5 (NPY-5) receptor antagonists or agonists; eating disorders, diabetes dyslipidemia, hypertension, and sleep disorders; pyridazin-3-ylamino-substituted dibenzothiophenes and S-oxides thereof
09/22/2005US20050209225 Substituted indoles and their use as integrin antagonists
09/22/2005US20050209222 Pharmaceutically active compounds and methods of use
09/22/2005US20050209216 Inhibit the synthesis of TNF-alpha (TNF=tumor necrosis factor); use treating diseases linked to immune and inflammatory disorders or as analgesics; e.g. 7-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)quinoline
09/22/2005US20050209192 Autoimmune disorders; modulating protein kinase C activity
09/22/2005US20050209176 Compounds that interact with kinases
09/22/2005US20050208619 29 human secreted proteins
09/22/2005US20050208605 An antibody or fragment (especially a monoclonal antibody) that binds to specific antigens for use in the diagnosis and treatment of heart, kidney and inflammatory diseases
09/22/2005US20050208525 Nucleotide sequences coding preferential polypeptide for use in the treatment defects in immune and inflammatory response
09/22/2005US20050208484 Isolated nucleic acid molecules encoding human drugmetobolizing proteins
09/22/2005US20050208163 anticholesterol agents contains Persea americana var. drymifolia leaf plant extract; nutraceuticals
09/22/2005US20050208137 comprising angiogenesis inhibitor retinoic acid, taxol and polymeric carrier polylactone; treating cancer, angiogenic-dependent diseases, embolizing blood vessels, and eliminating biliary, urethral, esophageal, tracheal/bronchial obstructions, corneal neovascularization; coated stents with the mixture
09/22/2005US20050208135 Monocompartment osmotic controlled drug delivery system
09/22/2005US20050208126 Chemical ifg-i composition for the treatment and prevention of neurodgenerative diseases
09/22/2005US20050208125 Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatmetn of central nervous system disturbances
09/22/2005US20050208124 Drugs containing riboflavin-type compounds
09/22/2005US20050208092 Drug delivery; vascular disease; stents, grafts, anastomotic devices, perivascular wraps, sutures and staples
09/22/2005US20050208081 With water miscible solubilizer; phosphodiesterase inhibitors; cardiovascular disorders
09/22/2005US20050208046 TWEAK receptor
09/22/2005US20050208016 derivatives effectively block the inflammatory effects of RANTES, and are useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma/atherosclerosis, and rheumatoid arthritis, hiv
09/22/2005US20050208001 rosacea, intrinsic or chronological aging, pigmentation, seborrhoeic function, barrier function, epidermal lipid secretion, wound healing, atrophies, ulcers, immune system, cardiovascular system disorders; 6-(5,6,7,8-tetrahydro-5,5,8,8-tetra-methylnaphthalene-2-carbonyl)naphthalene-2-carboxylic acid
09/22/2005CA2560098A1 2-aminoquinazoline derivative
09/22/2005CA2559826A1 Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method
09/22/2005CA2499220A1 Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
09/21/2005EP1577388A1 Adiponectin promoter and use thereof
09/21/2005EP1577323A1 Metastin derivative and use thereof
09/21/2005EP1577317A1 Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
09/21/2005EP1577309A1 Optically active dihydropyridine derivative
09/21/2005EP1577302A1 Novel ethylenediamine derivatives
09/21/2005EP1577296A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their use
09/21/2005EP1577295A1 Process for preparing 2-oxo-1-pyrrolidine derivatives as intermediates
09/21/2005EP1577288A1 Selective estrogen receptor modulators
09/21/2005EP1576964A1 Protease inhibitor
09/21/2005EP1576958A1 An composition containing triterpenoid saponins extracted from bamboo, and the preparation method and use thereof
09/21/2005EP1576954A1 Preferential inhibition of release of pro-inflammatory cytokines
09/21/2005EP1576168A2 Therapeutic polypeptides nucleic acids encoding same and methods of use
09/21/2005EP1576160A2 Borrelidin-producing polyketide synthase and its use
09/21/2005EP1576088A2 Dominant negative proteins and methods thereof
09/21/2005EP1576086A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/21/2005EP1575984A2 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade
09/21/2005EP1575976A2 Methods and compositions for therapeutic use of rna interference
09/21/2005EP1575916A2 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
09/21/2005EP1575607A1 Vanilloid receptor-2 ligands for treating anxiety or depression
09/21/2005EP1575589A1 Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
09/21/2005EP1575581A1 Combinations of valsartan with cox-2 inhibitors
09/21/2005EP1575567A1 Method and reagents for treating or preventing atherosclerosis and diseases associated therewith
09/21/2005EP1575528A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
09/21/2005EP1575524A2 Proliferated cell lines and uses thereof
09/21/2005EP1575521A2 Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof
09/21/2005EP1575511A2 A new target for angiogenesis and anti-angiogenesis therapy
09/21/2005EP1575499A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
09/21/2005EP1575495A2 Compounds and methods
09/21/2005EP1575480A2 Compositions and methods for the treatment of immune related diseases
09/21/2005EP1575414A2 Methods and devices for detection and therapy of atheromatous plaque
09/21/2005EP1542728A4 Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same
09/21/2005EP1438038A4 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
09/21/2005EP1404377B1 Improved chelator conjugates
09/21/2005EP1377560B1 Piperazine derivatives as tachykinin antagonists
09/21/2005EP1355641B1 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
09/21/2005EP1339694B1 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists
09/21/2005EP1303501B1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
09/21/2005EP1296689B1 Method of administering bisphosphonates
09/21/2005EP1294679B1 Beta-amino acid nitrile derivatives
09/21/2005EP1282602B1 Propanoic acid derivatives as integrin receptor antagonists
09/21/2005EP1265862B1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
09/21/2005EP1137640B1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
09/21/2005EP1061805B1 Regulation of endogenous gene expression in cells using zinc finger proteins
09/21/2005EP0996459B1 Use of exendins and agonists thereof for the reduction of food intake
1 ... 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 ... 1595